100 related articles for article (PubMed ID: 27221663)
1. Chronic Administration of Visfatin Ameliorated Diabetic Nephropathy in Type 2 Diabetic Mice.
Kang YS; Lee MH; Song HK; Kim JE; Ghee JY; Cha JJ; Lee JE; Kim HW; Han JY; Cha DR
Kidney Blood Press Res; 2016; 41(3):311-24. PubMed ID: 27221663
[TBL] [Abstract][Full Text] [Related]
2. Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice.
Nam DH; Lee MH; Kim JE; Song HK; Kang YS; Lee JE; Kim HW; Cha JJ; Hyun YY; Kim SH; Han SY; Han KH; Han JY; Cha DR
Endocrinology; 2012 Mar; 153(3):1387-96. PubMed ID: 22234468
[TBL] [Abstract][Full Text] [Related]
3. CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice.
Kang YS; Lee MH; Song HK; Ko GJ; Kwon OS; Lim TK; Kim SH; Han SY; Han KH; Lee JE; Han JY; Kim HK; Cha DR
Kidney Int; 2010 Nov; 78(9):883-94. PubMed ID: 20686445
[TBL] [Abstract][Full Text] [Related]
4. Activation of farnesoid X receptor downregulates visfatin and attenuates diabetic nephropathy.
Zhou B; Feng B; Qin Z; Zhao Y; Chen Y; Shi Z; Gong Y; Zhang J; Yuan F; Mu J
Mol Cell Endocrinol; 2016 Jan; 419():72-82. PubMed ID: 26450152
[TBL] [Abstract][Full Text] [Related]
5. Visfatin: a new player in mesangial cell physiology and diabetic nephropathy.
Song HK; Lee MH; Kim BK; Park YG; Ko GJ; Kang YS; Han JY; Han SY; Han KH; Kim HK; Cha DR
Am J Physiol Renal Physiol; 2008 Nov; 295(5):F1485-94. PubMed ID: 18768589
[TBL] [Abstract][Full Text] [Related]
6. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
Ko GJ; Kang YS; Han SY; Lee MH; Song HK; Han KH; Kim HK; Han JY; Cha DR
Nephrol Dial Transplant; 2008 Sep; 23(9):2750-60. PubMed ID: 18388116
[TBL] [Abstract][Full Text] [Related]
7. Rice bran protein hydrolysates attenuate diabetic nephropathy in diabetic animal model.
Boonloh K; Lee ES; Kim HM; Kwon MH; Kim YM; Pannangpetch P; Kongyingyoes B; Kukongviriyapan U; Thawornchinsombut S; Lee EY; Kukongviriyapan V; Chung CH
Eur J Nutr; 2018 Mar; 57(2):761-772. PubMed ID: 28004272
[TBL] [Abstract][Full Text] [Related]
8. Protective role of oryeongsan against renal inflammation and glomerulosclerosis in db/db mice.
Yoon JJ; Lee YJ; Kang DG; Lee HS
Am J Chin Med; 2014; 42(6):1431-52. PubMed ID: 25482677
[TBL] [Abstract][Full Text] [Related]
9. Plasma concentration of visfatin is a new surrogate marker of systemic inflammation in type 2 diabetic patients.
Kang YS; Song HK; Lee MH; Ko GJ; Cha DR
Diabetes Res Clin Pract; 2010 Aug; 89(2):141-9. PubMed ID: 20409603
[TBL] [Abstract][Full Text] [Related]
10. Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy.
Eyileten T; Sonmez A; Saglam M; Cakir E; Caglar K; Oguz Y; Vural A; Yenicesu M; Yilmaz MI
Nephrology (Carlton); 2010 Mar; 15(2):225-9. PubMed ID: 20470283
[TBL] [Abstract][Full Text] [Related]
11. Visfatin is upregulated in type-2 diabetic rats and targets renal cells.
Kang YS; Song HK; Lee MH; Ko GJ; Han JY; Han SY; Han KH; Kim HK; Cha DR
Kidney Int; 2010 Jul; 78(2):170-81. PubMed ID: 20375985
[TBL] [Abstract][Full Text] [Related]
12. Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095.
Arakawa K; Ishihara T; Oku A; Nawano M; Ueta K; Kitamura K; Matsumoto M; Saito A
Br J Pharmacol; 2001 Jan; 132(2):578-86. PubMed ID: 11159708
[TBL] [Abstract][Full Text] [Related]
13. Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome.
Nourbakhsh M; Nourbakhsh M; Gholinejad Z; Razzaghy-Azar M
Scand J Clin Lab Invest; 2015 Apr; 75(2):183-8. PubMed ID: 25723377
[TBL] [Abstract][Full Text] [Related]
14. Ezetimibe ameliorates early diabetic nephropathy in db/db mice.
Tamura Y; Murayama T; Minami M; Matsubara T; Yokode M; Arai H
J Atheroscler Thromb; 2012; 19(7):608-18. PubMed ID: 22498767
[TBL] [Abstract][Full Text] [Related]
15. SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice.
Sugaru E; Nakagawa T; Ono-Kishino M; Nagamine J; Tokunaga T; Kitoh M; Hume WE; Nagata R; Taiji M
Am J Physiol Renal Physiol; 2006 Apr; 290(4):F813-20. PubMed ID: 16278277
[TBL] [Abstract][Full Text] [Related]
16. Thyroid hormone ameliorates diabetic nephropathy in a mouse model of type II diabetes.
Lin Y; Sun Z
J Endocrinol; 2011 May; 209(2):185-91. PubMed ID: 21307121
[TBL] [Abstract][Full Text] [Related]
17. Farnesoid X receptor (FXR) agonist ameliorates systemic insulin resistance, dysregulation of lipid metabolism, and alterations of various organs in a type 2 diabetic kidney animal model.
Han SY; Song HK; Cha JJ; Han JY; Kang YS; Cha DR
Acta Diabetol; 2021 Apr; 58(4):495-503. PubMed ID: 33399988
[TBL] [Abstract][Full Text] [Related]
18. Correlation Between Circulating Visfatin and Nitric Oxide Metabolites Levels in Patients With Diabetic Nephropathy.
Akbarian N; Zarghami N; Mota A; Abediazar S; Abroon S; Mihanfar A; Amanzadeh M; Darbin A; Bannazadeh Baghi H; Rahmati-Yamchi M
Iran J Kidney Dis; 2018 May; 12(3):163-168. PubMed ID: 29891746
[TBL] [Abstract][Full Text] [Related]
19. [Association between both resistin, visfatin and insulin resistance as well as β cell function in the first-degree relatives of type 2 diabetes mellitus].
Zhang XJ; Wang Z; Li HH; Yu L; Gao S
Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Dec; 31(12):1393-6. PubMed ID: 21223671
[TBL] [Abstract][Full Text] [Related]
20. Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy.
Alghasham AA; Barakat YA
Saudi Med J; 2008 Feb; 29(2):185-92. PubMed ID: 18246224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
